Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Study of Adalimumab in Moderate to Severe Hidradenitis Suppurativa
2011-003478-98Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in hidradenitis suppurativa (HS), sponsored by AbbVie Inc. Primary endpoints: Improvement in lesion counts, Other lesion assessments and 1 more. Started Apr 2012; status: completed.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2011-003478-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003478-98.